
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RYTM | NASDAQ | USD | Real-time | |
1RV | Frankfurt | EUR | Delayed | |
1RV | TradeGate | EUR | Delayed |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Christophe R. Jean | 65 | 2015 | Independent Director |
David P. Meeker | 67 | 2015 | Chairman, President & CEO |
David W. J. McGirr | 71 | 2015 | Independent Director |
William W. Chin | 76 | - | Member of Scientific Advisory Board |
John M. Amatruda | 80 | - | Member of Scientific Advisory Board |
Lee M. Kaplan | - | - | Chairman of Scientific Advisory Board |
Stuart A. Arbuckle | 59 | 2019 | Independent Director |
Elizabeth Stoner | 75 | - | Member of Scientific Advisory Board |
Edward T. Mathers | 65 | 2013 | Lead Independent Director |
Michael C. Camilleri | - | - | Member of Scientific Advisory Board |
Jennifer L. Good | 60 | 2019 | Independent Director |
Camille L. Bedrosian | 72 | 2020 | Independent Director |
Lynn A. Tetrault | 62 | 2020 | Independent Director |
Christophe R. Jean | 70 | 2015 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review